FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025658051> ?p ?o ?g. }

• W2025658051 endingPage "381" @default.
• W2025658051 startingPage "375" @default.
• W2025658051 abstract "This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was 74% including 44% complete responses (CR); median progression-free survival (PFS) was 12·4 months. The 13 rituximab refractory patients had an ORR of 61·5% (four CR/unconfirmed CR). The ORR was 77% in the 22 follicular lymphoma patients (nine CR/unconfirmed CR). At a median follow-up time of 43 months, the median duration of response and time to next therapy were 15·4 and 37·4 months, respectively. Most common grade 3/4 adverse events were lymphopenia (45%), neutropenia (55%), fatigue (23%) and hyponatraemia (9%). The ORR and PFS in patients with low-affinity FCGR3A polymorphisms (F/F and F/V) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent NHL." @default.
• W2025658051 created "2016-06-24" @default.
• W2025658051 creator A5006953179 @default.
• W2025658051 creator A5021579716 @default.
• W2025658051 creator A5033098542 @default.
• W2025658051 creator A5041854716 @default.
• W2025658051 creator A5045079164 @default.
• W2025658051 creator A5046589665 @default.
• W2025658051 creator A5049722711 @default.
• W2025658051 creator A5060558335 @default.
• W2025658051 date "2014-03-07" @default.
• W2025658051 modified "2023-10-05" @default.
• W2025658051 title "Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma" @default.
• W2025658051 cites W1912693401 @default.
• W2025658051 cites W1965962344 @default.
• W2025658051 cites W1988591205 @default.
• W2025658051 cites W1990765152 @default.
• W2025658051 cites W2000302977 @default.
• W2025658051 cites W2027362911 @default.
• W2025658051 cites W2029409133 @default.
• W2025658051 cites W2044360617 @default.
• W2025658051 cites W2055352702 @default.
• W2025658051 cites W2063157305 @default.
• W2025658051 cites W2063463053 @default.
• W2025658051 cites W2095119858 @default.
• W2025658051 cites W2099308699 @default.
• W2025658051 cites W2116194748 @default.
• W2025658051 cites W2120775216 @default.
• W2025658051 cites W2127749132 @default.
• W2025658051 cites W2135321054 @default.
• W2025658051 cites W2136326451 @default.
• W2025658051 cites W2154643481 @default.
• W2025658051 cites W2168450724 @default.
• W2025658051 doi "https://doi.org/10.1111/bjh.12755" @default.
• W2025658051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24606326" @default.
• W2025658051 hasPublicationYear "2014" @default.
• W2025658051 type Work @default.
• W2025658051 sameAs 2025658051 @default.
• W2025658051 citedByCount "70" @default.
• W2025658051 countsByYear W20256580512014 @default.
• W2025658051 countsByYear W20256580512015 @default.
• W2025658051 countsByYear W20256580512016 @default.
• W2025658051 countsByYear W20256580512017 @default.
• W2025658051 countsByYear W20256580512018 @default.
• W2025658051 countsByYear W20256580512019 @default.
• W2025658051 countsByYear W20256580512020 @default.
• W2025658051 countsByYear W20256580512021 @default.
• W2025658051 countsByYear W20256580512022 @default.
• W2025658051 countsByYear W20256580512023 @default.
• W2025658051 crossrefType "journal-article" @default.
• W2025658051 hasAuthorship W2025658051A5006953179 @default.
• W2025658051 hasAuthorship W2025658051A5021579716 @default.
• W2025658051 hasAuthorship W2025658051A5033098542 @default.
• W2025658051 hasAuthorship W2025658051A5041854716 @default.
• W2025658051 hasAuthorship W2025658051A5045079164 @default.
• W2025658051 hasAuthorship W2025658051A5046589665 @default.
• W2025658051 hasAuthorship W2025658051A5049722711 @default.
• W2025658051 hasAuthorship W2025658051A5060558335 @default.
• W2025658051 hasBestOaLocation W20256580511 @default.
• W2025658051 hasConcept C121332964 @default.
• W2025658051 hasConcept C126322002 @default.
• W2025658051 hasConcept C141071460 @default.
• W2025658051 hasConcept C142424586 @default.
• W2025658051 hasConcept C143998085 @default.
• W2025658051 hasConcept C197934379 @default.
• W2025658051 hasConcept C2776063141 @default.
• W2025658051 hasConcept C2776364478 @default.
• W2025658051 hasConcept C2777063308 @default.
• W2025658051 hasConcept C2778850193 @default.
• W2025658051 hasConcept C2779338263 @default.
• W2025658051 hasConcept C2780653079 @default.
• W2025658051 hasConcept C29730261 @default.
• W2025658051 hasConcept C71924100 @default.
• W2025658051 hasConcept C87355193 @default.
• W2025658051 hasConcept C90924648 @default.
• W2025658051 hasConceptScore W2025658051C121332964 @default.
• W2025658051 hasConceptScore W2025658051C126322002 @default.
• W2025658051 hasConceptScore W2025658051C141071460 @default.
• W2025658051 hasConceptScore W2025658051C142424586 @default.
• W2025658051 hasConceptScore W2025658051C143998085 @default.
• W2025658051 hasConceptScore W2025658051C197934379 @default.
• W2025658051 hasConceptScore W2025658051C2776063141 @default.
• W2025658051 hasConceptScore W2025658051C2776364478 @default.
• W2025658051 hasConceptScore W2025658051C2777063308 @default.
• W2025658051 hasConceptScore W2025658051C2778850193 @default.
• W2025658051 hasConceptScore W2025658051C2779338263 @default.
• W2025658051 hasConceptScore W2025658051C2780653079 @default.
• W2025658051 hasConceptScore W2025658051C29730261 @default.
• W2025658051 hasConceptScore W2025658051C71924100 @default.
• W2025658051 hasConceptScore W2025658051C87355193 @default.
• W2025658051 hasConceptScore W2025658051C90924648 @default.
• W2025658051 hasIssue "3" @default.
• W2025658051 hasLocation W20256580511 @default.
• W2025658051 hasLocation W20256580512 @default.
• W2025658051 hasOpenAccess W2025658051 @default.
• W2025658051 hasPrimaryLocation W20256580511 @default.
• W2025658051 hasRelatedWork W1998723026 @default.
• W2025658051 hasRelatedWork W2025658051 @default.

• next